Primary Prevention of Cardiovascular Disease with Statins in the Elderly

Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Cardiovascular Disease and Stroke

Abstract

Owing to the progressive aging of the population, and the fact that cardiovascular disease (CVD) is the leading cause of death among the elderly, the prevention of CVD in the elderly is becoming increasingly important. Although there is no doubt that statin treatment should be used for reducing CVD risk in the elderly in secondary prevention in the same way as in younger individuals, the evidence that such treatment really prolongs life in elderly subjects in primary prevention is still not so clear. However, it seems that it does reduce CVD morbidity in elderly individuals. Because of limited evidence regarding the benefit of such therapy, particularly in very old subjects (older than 80–85 years), the decision whether to treat or not treat an elderly individual with statins in primary prevention should be based on good clinical judgment and considering the individual subject’s situation regarding comorbidities, polypharmacy, and possible adverse effects.

Keywords

Cardiovascular disease Statins Elderly LDL-cholesterol Adverse effects Guidelines 

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Merkler M, Reiner Ž. The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundam Clin Pharmacol. 2007;21 Suppl 2:1–3.PubMedCrossRefGoogle Scholar
  2. 2.
    Moran A, Zhao D, Gu D, Coxson P, Chen CS, Cheng J, et al. The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China. BMC Public Health. 2008;8:394.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Odden MC, Coxson PG, Moran A, Lightwood JM, Goldman L, Bibbins-Domingo K. The impact of the aging population on coronary heart disease in the United States. Am J Med. 2011;124(9):827–33.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28(19):2375–414.PubMedCrossRefGoogle Scholar
  5. 5.
    Ducharme N, Radhamma R. Hyperlipidemia in the elderly. Clin Geriatr Med. 2008;24(3):471–87.PubMedCrossRefGoogle Scholar
  6. 6.
    Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS, et al. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. Arch Intern Med. 1998;158(16):1761–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart. 2002;88(1):25–9.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291(15):1864–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Gnavi R, Migliardi A, Demaria M, Petrelli A, Caprioglio A, Costa G. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health. 2007;17(5):492–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Niska R, Han B. Statins for secondary cardiovascular disease prevention for older primary care patients. J Natl Med Assoc. 2009;101(7):705–10.PubMedGoogle Scholar
  11. 11.
    Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol. 2010;4(6):483–90.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.••
    Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10(8):453–64. This is the most recent and most comprehensive review of the use of statins in the primary prevention of CVD, including in the elderly.PubMedCrossRefGoogle Scholar
  13. 13.••
    Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818. These are the first European guidelines for the management of dyslipidemias containing an important section on the treatment of dyslipidemias in the elderly.PubMedCrossRefGoogle Scholar
  14. 14.
    Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–701.PubMedCrossRefGoogle Scholar
  15. 15.••
    Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.1161/01.cir.0000437738.63853.7a. These are the most recent US guidelines on the treatment of hypercholesterolemia, mentioning also the treatment of the elderly.PubMedCentralGoogle Scholar
  16. 16.
    Ray KK, Kastelein JJP, Boekholdt SM, Nicholls SJ, Khaw K-T, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults - the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014; doi10.1093/eurheartj/ehu107
  17. 17.
    Graham I, Cooney MT, Bradley D, Dudina A, Reiner Ž. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep. 2012;14(6):709–20.PubMedCrossRefGoogle Scholar
  18. 18.
    De Backer G, Catapano AL, Chapman J, Graham I, Reiner Ž, Perk J, et al. Guidelines on CVD prevention: confusing or complementary? Atherosclerosis. 2013;226(1):299–300.PubMedCrossRefGoogle Scholar
  19. 19.
    National Heart, Blood, and Lung Institute. NHLBI, estimate of 10-year risk for CHD. http://www.nhlbi.nih.gov/guidelines/cholesterol/risk_tbl.htm. Accessed February 14, 2014.
  20. 20.
    Zannad F, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmsen L, De Backer G, et al. Prevention of cardiovascular disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) workshop of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy. Eur J Prev Cardiol. 2012;19(6):1454–64.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Zannad F, De Backer G, Graham I, Lorenz M, Mancia G, Morrow DA, et al. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. Fundam Clin Pharmacol. 2012;26(2):163–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.CrossRefGoogle Scholar
  23. 23.
    Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58.PubMedCrossRefGoogle Scholar
  26. 26.
    Nakaya N, Mizuno K, Ohashi Y, Teramoto T, Yokoyama S, Hirahara K, et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging. 2011;28(9):681–92.PubMedCrossRefGoogle Scholar
  27. 27.
    Lemaitre RN, Psaty BM, Heckbert SR, Kronmal RA, Newman AB, Burke GL. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med. 2002;162(12):1395–400.PubMedCrossRefGoogle Scholar
  28. 28.
    Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488–96.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Zieman SJ, Ouyang P. Statins for primary prevention in older adults: who is high risk, who is old, and what denotes primary prevention? Ann Intern Med. 2010;152(8):528–30.PubMedCrossRefGoogle Scholar
  31. 31.••
    Savarese G, Gotto Jr AM, Paolillo S, D'Amore C, Losco T, Musella F, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62(22):2090–9. This article provides very recent data showing that in elderly subjects at high CVD risk but without established CVD, statins significantly reduce the incidence of myocardial infarction and stroke, but do not significantly prolong survival in the short term.PubMedCrossRefGoogle Scholar
  32. 32.
    Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10(3):373–87.PubMedCrossRefGoogle Scholar
  33. 33.
    Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109–24.PubMedCrossRefGoogle Scholar
  34. 34.
    Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Can J Cardiol. 2011 Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Canad. J Cardiol. 2011;27(5):635–62.Google Scholar
  35. 35.
    Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12(5):565–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS, Smith Jr SC, et al. Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther. 2009;14(1):49–58.PubMedCrossRefGoogle Scholar
  37. 37.
    Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47–59.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48(2):662–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Oni ET, Sinha P, Karim A, Martin SS, Blaha MJ, Agatston AS, et al. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease. Arch Med Res. 2014;45(1):52–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Younoszai Z, Li Z, Stepanova M, Erario M, Cable R, Younossi ZM. Statin use is not associated with liver related mortality. Ann Hepatol. 2013–2014;13(1):84–90.Google Scholar
  41. 41.
    Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115(1):27–33.PubMedCrossRefGoogle Scholar
  42. 42.
    Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134(10):931–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357(15):1477–86.PubMedCrossRefGoogle Scholar
  44. 44.
    Cholesterol Treatment Trialists’ (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE. 2012;7(1):e29849.PubMedCrossRefGoogle Scholar
  45. 45.
    Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.PubMedCrossRefGoogle Scholar
  46. 46.
    Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–64.PubMedCrossRefGoogle Scholar
  47. 47.
    Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60(14):1231–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Ma T, Tien L, Fang C-L, Liou YS, Jong GP. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977–83.PubMedCrossRefGoogle Scholar
  49. 49.
    Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172(2):144–52.PubMedCrossRefGoogle Scholar
  50. 50.
    Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357–62.PubMedCrossRefGoogle Scholar
  51. 51.
    Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–71.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108(7):538–46.PubMedCrossRefGoogle Scholar
  54. 54.
    Jakovljević M, Reiner Z, Miličić D. Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatr Danub. 2007;19(4):270–81.PubMedGoogle Scholar
  55. 55.
    Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013;131(11):1427–34.PubMedCrossRefGoogle Scholar
  56. 56.
    Sheppard JP, Singh S, Fletcher K, et al. Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ. 2012;345:e4535.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Upmeier E, Korhonen MJ, Helin-Salmivaara A, Huupponen R. Statin use among older Finns stratified according to cardiovascular risk. Eur J Clin Pharmacol. 2013;69(2):261–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Chokshi NP, Messerli FH, Sutin D, Supariwala AA, Shah NR. Appropriateness of statins in patients aged ≥80 years and comparison to other age groups. Am J Cardiol. 2012;110(10):1477–81.PubMedCrossRefGoogle Scholar
  59. 59.
    Dornbrook-Lavender KA, Roth MT, Pieper JA. Secondary prevention of coronary heart disease in the elderly. Ann Pharmacother. 2003;37(12):1867–76.PubMedCrossRefGoogle Scholar
  60. 60.
    Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410–21.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010;4(6):462–71.PubMedCrossRefGoogle Scholar
  62. 62.
    Reiner Ž, Sonicki Z, Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev Med. 2010;51(6):494–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Reiner Ž, Sonicki Z, Tedeschi-Reiner E. Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis. 2010;213(2):598–603.PubMedCrossRefGoogle Scholar
  64. 64.
    Reiner Ž, Sonicki Z, Tedeschi-Reiner E. The perception and knowledge of cardiovascular risk factors among medical students. Croat Med J. 2012;53(3):278–84.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Reiner Ž, De Bacquer D, Kotseva K, Prugger C, De Backer G, Wood D, et al. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis. 2013;231(2):300–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Reiner Ž, Tedeschi-Reiner E. Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat Med J. 2013;54(4):339–45.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Internal Medicine, University Hospital Centre Zagreb, School of MedicineUniversity of ZagrebZagrebCroatia

Personalised recommendations